RT Journal Article
T1 Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.
A1 Custodio, A
A1 Carmona-Bayonas, A
A1 Jiménez-Fonseca, P
A1 Sánchez, M L
A1 Viudez, A
A1 Hernández, R
A1 Cano, J M
A1 Echavarria, I
A1 Pericay, C
A1 Mangas, M
A1 Visa, L
A1 Buxo, E
A1 García, T
A1 Rodríguez Palomo, A
A1 Álvarez Manceñido, F
A1 Lacalle, A
A1 Macias, I
A1 Azkarate, A
A1 Ramchandani, A
A1 Fernández Montes, A
A1 López, C
A1 Longo, F
A1 Sánchez Bayona, R
A1 Limón, M L
A1 Díaz-Serrano, A
A1 Hurtado, A
A1 Madero, R
A1 Gómez, C
A1 Gallego, J
AB To develop and validate a nomogram and web-based calculator to predict overall survival (OS) in Caucasian-advanced oesophagogastric adenocarcinoma (AOA) patients undergoing first-line combination chemotherapy. Nine hundred twenty-four AOA patients treated at 28 Spanish teaching hospitals from January 2008 to September 2014 were used as derivation cohort. The result of an adjusted-Cox proportional hazards regression was represented as a nomogram and web-based calculator. The model was validated in 502 prospectively recruited patients treated between October 2014 and December 2016. Harrell's c-index was used to evaluate discrimination. The nomogram includes seven predictors associated with OS: HER2-positive tumours treated with trastuzumab, Eastern Cooperative Oncology Group performance status, number of metastatic sites, bone metastases, ascites, histological grade, and neutrophil-to-lymphocyte ratio. Median OS was 5.8 (95% confidence interval (CI), 4.5-6.6), 9.4 (95% CI, 8.5-10.6), and 14 months (95% CI, 11.8-16) for high-, intermediate-, and low-risk groups, respectively (P We developed and validated a straightforward model to predict survival in Caucasian AOA patients initiating first-line polychemotherapy. This model can contribute to inform clinical decision-making and optimise clinical trial design.
YR 2017
FD 2017-05-02
LK http://hdl.handle.net/10668/11158
UL http://hdl.handle.net/10668/11158
LA en
DS RISalud
RD Apr 4, 2025